FDA Approval Marks First CRISPR-Based Therapy for Sickle Cell Disease
The FDA approved Casgevy and Lyfgenia in December 2023, including the first FDA-approved CRISPR/Cas9 therapy for sickle cell disease in patients 12 and older.
Start from core concepts, move into advanced biotech, and practice with visual lessons and research-backed explainers.
1. Learn Foundations
Begin with core concepts like cell biology, genetics, and physiology.
2. Practice with Visuals
Use lectures, infographics, and simulations to strengthen understanding.
3. Apply in Research
Connect concepts to real discoveries and research-grade thinking.
The FDA approved Casgevy and Lyfgenia in December 2023, including the first FDA-approved CRISPR/Cas9 therapy for sickle cell disease in patients 12 and older.
New findings suggest environmental toxic exposures can shift epigenetic aging markers.
Researchers report secondary social and health harms from drug deaths extending beyond mortality counts.
Combine structured learning modules with BiologyBytes AI Lab for deeper understanding.